Synlogic (SYBX) Competitors $1.69 -0.02 (-1.23%) As of 03:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SYBX vs. APLT, INKT, VNRX, ALXO, ANL, CELU, GNTA, MNOV, GANX, and ABVCShould you be buying Synlogic stock or one of its competitors? The main competitors of Synlogic include Applied Therapeutics (APLT), MiNK Therapeutics (INKT), VolitionRx (VNRX), ALX Oncology (ALXO), Adlai Nortye (ANL), Celularity (CELU), Genenta Science (GNTA), MediciNova (MNOV), Gain Therapeutics (GANX), and ABVC BioPharma (ABVC). These companies are all part of the "pharmaceutical products" industry. Synlogic vs. Its Competitors Applied Therapeutics MiNK Therapeutics VolitionRx ALX Oncology Adlai Nortye Celularity Genenta Science MediciNova Gain Therapeutics ABVC BioPharma Applied Therapeutics (NASDAQ:APLT) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings. Do insiders and institutionals have more ownership in APLT or SYBX? 98.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 63.4% of Synlogic shares are held by institutional investors. 1.6% of Applied Therapeutics shares are held by company insiders. Comparatively, 3.0% of Synlogic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is APLT or SYBX more profitable? Synlogic's return on equity of -8.09% beat Applied Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Applied TherapeuticsN/A -354.24% -144.16% Synlogic N/A -8.09%-5.50% Which has more risk & volatility, APLT or SYBX? Applied Therapeutics has a beta of 2.06, meaning that its stock price is 106% more volatile than the S&P 500. Comparatively, Synlogic has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Do analysts prefer APLT or SYBX? Applied Therapeutics presently has a consensus price target of $6.10, suggesting a potential upside of 1,270.79%. Given Applied Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Applied Therapeutics is more favorable than Synlogic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Applied Therapeutics 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Synlogic 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger valuation & earnings, APLT or SYBX? Synlogic has lower revenue, but higher earnings than Applied Therapeutics. Synlogic is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApplied Therapeutics$460K139.31-$105.62M-$0.45-0.99Synlogic$10K1,976.13-$23.36M-$0.08-21.11 Does the media refer more to APLT or SYBX? In the previous week, Applied Therapeutics had 1 more articles in the media than Synlogic. MarketBeat recorded 1 mentions for Applied Therapeutics and 0 mentions for Synlogic. Applied Therapeutics' average media sentiment score of 1.57 beat Synlogic's score of 1.00 indicating that Applied Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Applied Therapeutics Very Positive Synlogic Positive SummaryApplied Therapeutics beats Synlogic on 9 of the 15 factors compared between the two stocks. Get Synlogic News Delivered to You Automatically Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SYBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYBX vs. The Competition Export to ExcelMetricSynlogicMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.48M$3.14B$5.80B$10.37BDividend YieldN/A2.37%5.86%4.62%P/E Ratio-20.8121.2876.7726.93Price / Sales1,976.13247.68448.6288.63Price / CashN/A45.4837.2260.63Price / Book1.559.6413.766.37Net Income-$23.36M-$52.92M$3.29B$271.38M7 Day Performance14.90%1.19%0.77%2.30%1 Month Performance17.70%5.71%5.13%7.74%1 Year Performance12.60%12.17%83.96%31.18% Synlogic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYBXSynlogic1.4126 of 5 stars$1.69-1.2%N/A+13.2%$19.48M$10K-20.8180Positive NewsShort Interest ↓APLTApplied Therapeutics4.0563 of 5 stars$0.44-7.1%$6.10+1,285.4%-91.2%$68.25M$460K-0.9830News CoveragePositive NewsINKTMiNK Therapeutics3.7317 of 5 stars$15.83+7.0%$37.50+136.9%+89.8%$66.94MN/A-5.5030News CoverageNegative NewsShort Interest ↓Gap DownVNRXVolitionRx2.1401 of 5 stars$0.61+1.5%$3.50+472.8%-4.7%$65.74M$1.32M-1.7080ALXOALX Oncology3.5586 of 5 stars$1.11-9.0%$3.30+197.3%-51.8%$65.33MN/A-0.5040ANLAdlai Nortye2.0073 of 5 stars$1.70-2.9%$9.00+429.4%-19.6%$64.57M$5M0.00127Positive NewsCELUCelularity1.7375 of 5 stars$2.11-12.4%$6.00+184.4%-22.4%$64.33M$54.22M-0.66220Positive NewsGNTAGenenta Science2.5934 of 5 stars$3.49-0.3%$25.00+616.3%-4.8%$64.02MN/A0.007MNOVMediciNova2.1735 of 5 stars$1.26-2.3%$7.00+455.6%-27.8%$63.27M$134.60K-5.0410GANXGain Therapeutics2.1966 of 5 stars$1.75-0.6%$8.00+357.1%+5.7%$63.27M$50K-2.7820News CoverageGap UpABVCABVC BioPharma0.2928 of 5 stars$2.72+2.6%N/A+338.0%$62.39M$510K-16.0030Gap Up Related Companies and Tools Related Companies Applied Therapeutics Competitors MiNK Therapeutics Competitors VolitionRx Competitors ALX Oncology Competitors Adlai Nortye Competitors Celularity Competitors Genenta Science Competitors MediciNova Competitors Gain Therapeutics Competitors ABVC BioPharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SYBX) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWhy Peter Thiel Hid Gold in a VaultSilicon Valley billionaires hiding gold in vaults? Peter Thiel’s Palantir quietly diverted tens of millions...Golden Portfolio | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synlogic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synlogic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
